RY 174.39 2.4016% SHOP 149.115 2.5974% TD-PFM 24.63 -0.0811% TD-PFL 24.7 0.2028% TD 78.325 0.1214% ENB 60.6 1.3039% BN 80.4 1.9787% TRI 226.27 0.7525% CNQ 48.285 2.2771% CP 104.53 1.6038% CNR 151.74 1.5459% BMO 132.69 0.9203% BNS 78.845 0.1715% CSU 4600.2002 2.157% CM 91.15 0.474% MFC 45.79 1.6878% ATD 78.38 1.5285% NGT 60.14 0.0499% TRP 70.15 1.977% SU 57.44 0.5954%
Andlauer Healthcare Group Inc. (TSX: AND) is a Canada-based company that provides healthcare supply chain services. The Company offers a platform of customized third-party logistics (3PL) and transportation solutions for the healthcare sector.
Key highlights
Source: Company Presentation
Source: Company Filing, Analysis by Kalkine Group
Source: Company Filing, Analysis by Kalkine Group
Risks associated with investment
The company may see an increase in absenteeism from operational workers, such as warehouse associates, drivers, and owner operators, as a result of the pandemic, which might have a detrimental impact on operations. Furthermore, the entry of a new competitor into the business causes stiff rivalry and shifts in customer preferences may result in a loss of market share, affecting the company's revenue and cash flow.
Financial overview of FY 2021 (in millions of CAD)
Source: Company Filing
Top-10 Shareholders
The top 10 shareholders have been highlighted in the table, which forms around 44.87% of the total shareholding. Mawer Investment Management Ltd. and BMO Asset Management Inc. hold the company's maximum interests at 10.51% and 7.87%, respectively. The company's institutional ownership stood at 49.17% and ownership of the strategic entities stood at 2.13%. Higher institutional holding boosts the confidence in the mind of retail investors.
Valuation Methodology (Illustrative): EV to Sales
Analysis by Kalkine Group
Stock recommendation
In both the fourth quarter and the full year of 2021, the business saw substantial year-over-year revenue and profit growth, owing to the beneficial contributions of acquisitions and ongoing organic development. The acquisitions it made in 2021 considerably improved the client service offering and provided a solid foundation for future expansion in the United States. In addition, the company's recent acquisition of LSU adds to the platform's growth.
The company is expanding its presence in the United States, which is a significant plus. On the cost front, the firm is focusing on operational excellence and has reduced its operating expenditures as a percentage of sales by 130 basis points, which is a significant improvement. Furthermore, the outsourced healthcare logistics and transportation business in North America is expanding at a solid rate, boosting the company's confidence. Therefore, based on the above rationales and valuation, we recommend a "Buy" rating on the stock at the at the closing price of CAD 45.12 as on March 2, 2022.
One-Year Technical Price Chart (as on March 2, 2022). Source: REFINITIV, Analysis by Kalkine Group
Technical Analysis Summary
Disclaimer
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.